Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery

Journal of the Saudi Heart Association

Volumn 28, Issue 4, 2016, Pages 222-231

  Habib, Aly Makram ^a,b   Mousa, Ahmed Yehia ^b   Al Halees, Zohair ^c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c King Faisal Specialist Center and Research Center   (Saudi Arabia)

Author keywords

Bleeding; Cardiac surgery; rFVIIa

Indexed keywords

CREATININE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ADVERSE OUTCOME; AGED; ARTERY THROMBOSIS; ARTICLE; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; CARDIAC SURGERY INTENSIVE CARE UNIT; CEREBROVASCULAR ACCIDENT; CHEST TUBE; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART SURGERY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATOR; MEDIASTINITIS; OBSERVATIONAL STUDY; OPERATIVE BLOOD LOSS; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL PATIENT; SURVIVAL RATE;

EID: 84964889785     PISSN: 10167315     EISSN: 22125043     Source Type: Journal    
DOI: 10.1016/j.jsha.2016.03.001     Document Type: Article

References (45)

1. [1] Herwaldt, L.A., Swartzendruber, S.K., Zimmerman, M.B., Scholz, D.A., Franklin, J.A., Caldarone, C.A., Hemorrhage after coronary bypass graft procedures. Infect Control Hosp Epidemiol 24 (2003), 44–50.
2. [2] Taylor, G.J., Mikell, F.L., Moses, H.W., Dove, J.T., Katholi, R.E., Malik, S.A., et al. Determinants of hospital charges for coronary artery bypass surgery: the economic consequences of postoperative complications. Am J Cardiol 65 (1990), 309–313.
3. [3] Koch, C.G., Li, L., Sessler, D.I., Figueroa, P., Hoeltge, G.A., Mihaljevic, T., et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 358 (2008), 1229–1239.
4. [4] Dixon, B., Santamaria, J.D., Reid, D., Collins, M., Rechnitzer, T., Newcomb, A.E., et al. The association of blood transfusion with mortality after cardiac surgery: cause or confounding?. Transfusion 53 (2013), 19–27.
5. [5] Karkouti, K., Beattie, W.S., Wijeysundera, D.N., Yau, T.M., McCluskey, S.A., Ghannam, M., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: A propensity score-matched case-control analysis. Transfusion 45 (2005), 26–34.
6. [6] Diprose, P., Herbertson, M.J., O'Shaughnessy, D., Gill, R.S., Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95 (2005), 596–602.
7. [7] Von Heymann, C., Redlich, U., Jain, U., Kastrup, M., Schroeder, T., Sander, M., et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med 33 (2005), 2241–2246.
8. [8] Gelsomino, S., Lorusso, R., Romagnoli, S., Bevilacqua, S., De Cicco, G., Billè, G., et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. Eur J Cardiothorac Surg 33 (2008), 64–71.
9. [9] Tritapepe, L., De Santis, V., Vitale, D., Nencini, C., Pellegrini, F., Landoni, G., et al. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med 35 (2007), 1685–1690.
10. [10] Zangrillo, A., Mizzi, A., Biondi-Zoccai, G., Bignami, E., Calabrò, M.G., Pappalardo, F., et al. Recombinant activated factor VII in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 23 (2009), 34–40.
11. [11] Hedner, U., Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Haematol 38:Suppl. 12 (2001), 43–47.
12. [12] Nashef, S.A., Roques, F., Sharples, L.D., Nilsson, J., Smith, C., Goldstone, A.R., et al. EuroSCORE II. Eur J Cardiothorac Surg 41 (2012), 734–745.
13. [13] Kouchoukos Nicholas, T., Blackstone Eugene, H., Hanley Frank, L., Kirklin James, K., Barratt-Boyes, B.G., Cardiac surgery expert consult. 4th ed., 2013, Elsevier Saunders, Philadelphia.
14. [14] Gill, R., Herbertson, M., Vuylsteke, A., Olsen, P.S., von Heymann, C., Mythen, M., et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 120 (2009), 21–27.
15. [15] Karkouti, K., Yau, T., Riazi, S., Dattilo, K.M., Wasowicz, M., Meineri, M., et al. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 53 (2006), 802–809.
16. [16] Romagnoli, S., Bevilacqua, S., Gelsomino, S., Pradella, S., Ghilli, L., Rostagno, C., et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 102 (2006), 1320–1326.
17. [17] Bishop, C.V., Renwick, W.E.P., Hogan, C., Haeusler, M., Tuckfield, A., Tatoulis, J., Recombinant activated factor VII: Treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 81 (2006), 875–879.
18. [18] McCall, P., Story, D.A., Karapillai, D., Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 53 (2006), 926–933.
19. [19] Karkouti, K., Beattie, W.S., Arellano, R., Aye, T., Bussieres, J.S., Callum, J.L., et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 118 (2008), 331–338.
20. [20] Uber, W.E., Toole, J.M., Stroud, M.R., Haney, J.S., Lazarchick, J., Crawford, F.A. Jr, et al. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg 141 (2011), 1469–1477.
21. [21] Masud, F., Bostan, F., Chi, E., Pass, S.E., Samir, H., Stuebing, K., et al. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth 23 (2009), 28–33.
22. [22] Bowman, L., Uber, W., Stroud, M., Christiansen, L.R., Lazarchick, J., Crumbley, A.J. 3rd, et al. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery. Ann Thorac Surg 85 (2008), 1669–1677.
23. [23] Hacquard, M., Durand, M., Lecompte, T., Boini, S., Briançon, S., Carteaux, J.P., Off-label use of recombinant activated factor VII in intractable hemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centers (2005–7). Eur J Cardiothorac Surg 40 (2011), 1320–1327.
24. [24] Alfirevic, A., Duncan, A., You, J., Lober, C., Soltesz, E., Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 98 (2014), 618–624.
25. [25] Rao, V., Lobato, R., Bartlett, B., Klanjac, M., Mora-Mangano, C.T., Soran, P.D., et al. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth 28 (2014), 1221–1226.
26. [26] Raivio, P., Suojaranta-Ylinen, R., Kuitunen, A.H., Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 80 (2005), 66–71.
27. [27] Koncar, I.B., Davidovic, L.B., Savic, N., Sinđelić, R.B., Ilić, N., Dragas, M., et al. Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery. Vasc Surg 53 (2011), 1032–1038.
28. [28] Yan, W., Xuan, C., Ma, G., Zhang, L., Dong, N., Wang, Z., et al. Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations. J Cardiothorac Surg 9 (2014), 156–164.
29. [29] Andersen, N.D., Bhattacharya, S.D., Williams, J.B., Fosbol, E.L., Lockhart, E.L., Patel, M.B., et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 93 (2012), 1921–1929.
30. [30] Goksedef, D., Panagopoulos, G., Nassiri, N., Levine, R.L., Hountis, P.G., Plestis, K.A., Intraoperative use of recombinant activated factor VII during complex aortic surgery. J Thorac Cardiovasc Surg 143 (2012), 1198–1204.
31. [31] The Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris, V.A., Brown, J.R., Despotis, G.J., Hammon, J.W., Reece, T.B., et al. 2011 update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Ann Thorac Surg 91 (2011), 944–982.
32. [32] Willis, C., Bird, R., Mullany, D., Cameron, P., Phillips, L., Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang 98 (2010), 531–537.
33. [33] Donovan, P.J., Iedema, J., McLeod, D.S., Kubler, P., Pillans, P., Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland. ANZ J Surg 83 (2012), 149–154.
34. [34] AlGahtani, F., Alshaika, M., AlDiab, A., Recombinant activated factor VII in controlling bleeding in nonhemophiliac patients. Ann Saudi Med 30 (2010), 198–202.
35. [35] Yank, V., Tuohy, C.V., Logan, A.C., Bravata, D.M., Staudenmayer, K., Eisenhut, R., et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 154 (2011), 529–540.
36. [36] Hardy, J.F., Belisle, S., Van der Linden, P., Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Curr Opin Anaesthesiol 22 (2009), 95–99.
37. [37] Hardy, J.F., Belisle, S., Van der Linden, P., Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. Ann Thorac Surg 86 (2008), 1038–1048.
38. [38] Iau, P., Ong, V., Tze, W., Koh, P.L., Hartman, M., Use of activated recombinant factor VII in severe bleeding—evidence for efficacy and safety in trauma, postpartum hemorrhage, cardiac surgery, and gastrointestinal bleeding. Transfus Med Hemother 39 (2012), 139–150.
39. [39] Levi, M., Peters, M., Büller, H.R., Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33 (2005), 883–890.
40. [40] Levi, M., Levy, J.H., Andersen, H.F., Truloff, D., Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363 (2010), 1791–1800.
41. [41] Dunkley, S., Phillips, L., Mc Call, P., Brereton, J., Lindeman, R., Jankelowitz, G., et al. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg 85 (2008), 836–844.
42. [42] Warren, O., Mandal, K., Hadjianastassiou, V., Knowlton, L., Panesar, S., John, K., et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 83 (2007), 707–714.
43. [43] Zatta, A., McQuilten, Z., Kandane-Rathnayake, R., Isbister, J., Dunkley, S., Mcneil, J., et al. The Australian and New Zealand Hemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus 13 (2015), 86–99.
44. [44] Mitra, B., Phillips, L., Cameron, P., Billah, B., Reid, C., The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 38 (2010), 671–677.
45. [45] Luddington, R.J., Thrombelastography/thromboelastometry. Clin Lab Haematol 27 (2005), 81–90.